BORRBangladesh Open Research Repository
SearchSubmitAboutContact
BORRResearch for a Better Bangladesh.
AboutSubmit PaperContactTermsPolicyGitHub

© 2026 Bangladesh Open Research Repository.

Filters

Sort By

Sort by relevanceSort by dateSort by citations
Year Range
to

Results for “"Ada Keding"”

10 results

Cytisine for smoking cessation in patients with tuberculosis: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

Verified

Omara Dogar, Ada Keding, Rhian Gabe, Anna‐Marie Marshall et al.

Journal: The Lancet Global HealthYear: 2020Citations: 39

BACKGROUND: Smoking cessation is important in patients with tuberculosis because it can reduce the high rates of treatment failure and mortality. We aimed to assess the effectiveness and safety of cystine as a smoking cessation aid in patients with tuberculosis in Bangladesh and Pakistan. METHODS: W...

Health SciencesMedicinePhysiologyOpen Access
Read Source

Effect of quitting smoking on health outcomes during treatment for tuberculosis: secondary analysis of the TB & Tobacco Trial

Verified

Kamran Siddiqi, Ada Keding, Anna‐Marie Marshall, Omara Dogar et al.

Journal: ThoraxYear: 2021Citations: 28

Background Despite treatment, patients with tuberculosis (TB) who smoke have poorer outcomes compared with non-smokers. It is unknown, however, if quitting smoking during the 6 months of TB treatment improves TB outcomes. Methods The TB & Tobacco Trial was a double-blind, placebo-controlled rand...

Health SciencesMedicineInfectious DiseasesOpen Access
Read Source

The safety, effectiveness and cost‐effectiveness of cytisine in achieving six‐month continuous smoking abstinence in tuberculosis patients—protocol for a double‐blind, placebo‐controlled randomized trial

Verified

Omara Dogar, Deepa Barua, Melanie Boeckmann, Helen Elsey et al.

Journal: AddictionYear: 2018Citations: 26

BACKGROUND AND AIMS: Tuberculosis (TB) patients who quit smoking have much better disease outcomes than those who continue to smoke. In general populations, behavioural support combined with pharmacotherapy is the most effective strategy in helping people to quit. However, there is no evidence for t...

Life SciencesBiochemistry, Genetics and Molecular BiologyMolecular BiologyOpen Access
Read Source

Smoking prevalence among tuberculosis patients: A cross-sectionalstudy in Bangladesh and Pakistan

Verified

Anna‐Marie Marshall, Deepa Barua, Alex Mitchell, Ada Keding et al.

Journal: Tobacco Induced DiseasesYear: 2020Citations: 22

INTRODUCTION: Smoking has a negative impact on TB outcomes. We estimated the proportion of TB patients who smoke and are willing to quit in two high TB burden countries, Bangladesh and Pakistan. METHODS: A cross-sectional survey was conducted among TB patients to assess their eligibility and recruit...

Health SciencesMedicineInfectious DiseasesOpen Access
Read Source

Health worker and patient views on implementation of smoking cessation in routine tuberculosis care

Verified

Melanie Boeckmann, Sahil Khan Warsi, Maryam Noor, Omara Dogar et al.

Journal: npj Primary Care Respiratory MedicineYear: 2019Citations: 15

Smoking worsens tuberculosis (TB) outcomes. Persons with TB who smoke can benefit from smoking cessation. We report findings of a multi-country qualitative process evaluation assessing barriers and facilitators to implementation of smoking cessation behaviour support in TB clinics in Bangladesh and ...

Health SciencesHealth ProfessionsGeneral Health ProfessionsOpen Access
Read Source

A randomised controlled feasibility trial of Behavioural activation as a treatment for people with diabetes and depression: (DiaDeM feasibility trial)

Verified

Naveed Ahmed, Gerardo A. Zavala, Faraz Siddiqui, Faiza Aslam et al.

Journal: Journal of Affective DisordersYear: 2024Citations: 4

There is a lack of evidence on effective treatments for depression in people with T2DM, particularly in Low and Middle-Income Countries (LMICs). This study aims to test the feasibility and acceptability of a culturally adapted Behavioural Activation (BA) intervention (DiaDeM) for people with depress...

Health SciencesMedicineEndocrinology, Diabetes and MetabolismOpen Access
Read Source

Cost-utility of cytisine for smoking cessation over and above behavioural support in people with newly diagnosed pulmonary tuberculosis: an economic evaluation of a multicentre randomised controlled trial

Verified

Jinshuo Li, Steve Parrott, Ada Keding, Omara Dogar et al.

Journal: BMJ OpenYear: 2022Citations: 2

OBJECTIVES: To assess the cost-effectiveness of cytisine over and above brief behavioural support (BS) for smoking cessation among patients who are newly diagnosed with pulmonary tuberculosis (TB) in low-income and middle-income countries. DESIGN: An incremental cost-utility analysis was undertaken ...

Health SciencesMedicinePhysiologyOpen Access
Read Source

Effectiveness and cost-effectiveness of a culturally tailored Behavioural Activation intervention (DiaDeM) for treating Depression in Type 2 Diabetes: Protocol for a parallel arm, multi-country, randomised controlled trial in South Asia

Verified

Faraz Siddiqui, Faiza Aslam, Naveed Ahmed, Saima Afaq et al.

Journal: medRxivYear: 2023Citations: 1

Abstract Background The co-occurrence of depression among individuals with type 2 diabetes is a recognised global health problem and can lead to poorer health outcomes for both conditions. Behavioural activation is an evidence-based brief, low-cost psychological therapy which can be delivered by tra...

Social SciencesPsychologyApplied PsychologyOpen Access
Read Source

Addressing Depression in Diabetes Services in Bangladesh and Pakistan: Learnings from a Process Evaluation

Verified

Hannah Maria Jennings, Anum Naz, Ashraful Anas, Shaker Khan et al.

Journal: Global Implementation Research and ApplicationsYear: 2025
Health SciencesMedicineEndocrinology, Diabetes and Metabolism
Read Source

Multicentre Randomised Double-Blind Placebo Controlled Trial of Cytisine for Smoking Cessation in Smokers with Tuberculosis

Verified

Omara Dogar, Ada Keding, Rhian Gabe, Anna‐Marie Marshall et al.

Journal: The Lancet Global HealthYear: 2020
Life SciencesBiochemistry, Genetics and Molecular BiologyMolecular BiologyOpen Access
Read Source
PreviousPage 1 of 1Next